Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zealand Pharma
Biotech
Zealand sells rights to Takeda’s blood cancer drug for $100M
As the FDA mulls whether to approve Takeda and Protagonist’s rusfertide, Zealand sold its rights to the blood cancer drug in return for $100 million.
James Waldron
Aug 13, 2026 5:05am
Biogen R&D vet gets in Formation—Chutes & Ladders
Jul 24, 2026 8:30am
Fierce Pharma
Eli Lilly is the ‘clear winner’ from ADA, RBC analyst says
Jun 8, 2026 3:12pm
ADA: Tolerability questions linger for Boehringer's obesity drug
Jun 8, 2026 4:30am
ADA: Roche, Zealand make tolerability case for petrelintide
Jun 7, 2026 3:00am
Boehringer links dual agonist to 16.6% weight loss in phase 3
Apr 28, 2026 4:00am
